首页> 外文期刊>Artificial cells, nanomedicine, and biotechnology. >Carbon monoxide form of PEGylated hemoglobin protects myocardium against ischemia/reperfusion injury in diabetic and normal mice
【24h】

Carbon monoxide form of PEGylated hemoglobin protects myocardium against ischemia/reperfusion injury in diabetic and normal mice

机译:一氧化碳形式的聚乙二醇化血红蛋白可保护心肌免受糖尿病和正常小鼠的缺血/再灌注损伤

获取原文
       

摘要

We investigated the pre-clinical utility of carbon monoxide form of PEGylated hemoglobin (PEG-Hb also named SANGUINATE?) in myocardial infarction (MI) and in particular the response of diabetic tissues to superimposed ischemia/reperfusion injury. SANGUINATE? was evaluated in diabetic and normal mice subjected to 30 min of coronary artery ligation followed by either 48 h or 28 days of reperfusion. Our results demonstrate that SANGUINATE? was effective in reducing infarct size when administered either prior to left anterior descending coronary artery (LAD) occlusion or during reperfusion. This finding is an important step in exploring the efficacy of a pharmacoinvasive strategy using SANGUINATE? in patients with acute coronary syndromes.
机译:我们调查了一氧化碳形式的聚乙二醇化血红蛋白(PEG-Hb,也称为SANGUINATE?)在心肌梗死(MI)中的临床前效用,尤其是糖尿病组织对叠加性缺血/再灌注损伤的反应。 SANGUINATE?在接受冠状动脉结扎30分钟,然后再灌注48小时或28天的糖尿病和正常小鼠中评估TNF-α。我们的结果表明,SANGUINATE?在左冠状动脉前降支(LAD)闭塞之前或再灌注期间给药可有效减少梗塞面积。这一发现是探索使用SANGUINATE进行药物侵入疗法的功效的重要一步。在急性冠脉综合征患者中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号